Pular para o conteúdo
Merck
Todas as fotos(2)

Key Documents

View All Documentation

T4680

Sigma-Aldrich

Terazosin hydrochloride

≥98% (TLC), powder

Sinônimo(s):

1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(2)

About This Item

Fórmula empírica (Notação de Hill):
C19H25N5O4 · HCl
Número CAS:
63074-08-8
Peso molecular:
423.89
Número MDL:
MFCD00467965
Código UNSPSC:
12352200
ID de substância PubChem:
24278740
NACRES:
NA.77

Nível de qualidade

200

Ensaio

≥98% (TLC)

forma

powder

cor

white to off-white

solubilidade

H2O: soluble 19.60-20.40 mg/mL, clear, colorless to faintly yellow
methanol: 20 mg/mL, clear, colorless
ethanol: 4 mg/mL

originador

Abbott

cadeia de caracteres SMILES

Cl[H].COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4CCCO4

InChI

1S/C19H25N5O4.ClH/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H

chave InChI

IWSWDOUXSCRCKW-UHFFFAOYSA-N

Informações sobre genes

human ... ADRA1A(148) , ADRA1B(147) , ADRA1D(146)

Descrição geral

Terazosin hydrochloride is used to treat hypertension and benign prostatic hyperplasia (BPH). It is metabolised in the liver. It might be associated with dizziness, headache and asthenia. Terazosin hydrochloride is linked to acute generalized exanthematous pustulosis.

Aplicação

Terazosin hydrochloride has been used for orthogonality and similarity analysis using reversed-phase chromatographic studies5. Furthermore, terazosin has also been used for the evaluation of chemometric techniques to determine orthogonality and similarity in chromatographic methods6.

Ações bioquímicas/fisiológicas

α1-adrenoceptor antagonist.

Características e benefícios

This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Nota de preparo

Terazosin hydrochloride is soluble in water at 19.60 - 20.40 mg/ml and yields a clear, colorless to faint yellow solution. It is also soluble in ethanol at 4 mg/ml. Furthermore, the product is soluble in methanol at 20 mg/ml, with heat as needed, and yields a clear, colorless solution.

Pictogramas

Exclamation mark
GHS07

Palavra indicadora

Warning

Frases de perigo

H302

Declarações de precaução

P264 - P270 - P301 + P312 - P501

Classificações de perigo

Acute Tox. 4 Oral

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Equipamento de proteção individual

dust mask type N95 (US), Eyeshields, Gloves

Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Terazosin in the treatment of benign prostatic hyperplasia
Brawer MK, et al.
Archives of Family Medicine, 2(9), 929-929 (1993)
Terazosin
Titmarsh S and Monk JP
Drugs, 33(5), 461-477 (1987)
E Van Gyseghem et al.
Journal of pharmaceutical and biomedical analysis, 41(1), 141-151 (2005-12-15)
Several chemometric techniques were compared for their performance to determine the orthogonality and similarity between chromatographic systems. Pearson's correlation coefficient (r) based color maps earlier were used to indicate selectivity differences between systems. These maps, in which the systems were
A G Ramage et al.
European journal of pharmacology, 294(2-3), 645-650 (1995-12-29)
The effects of i.v. infusion of the alpha1-adrenoceptor antagonists doxazosin and terazosin (2 mg kg-1 h-1) on spontaneous hypogastric, renal and inferior cardiac nerve activity, spontaneous bladder contractions, blood pressure, heart rate and femoral arterial flow were investigated separately in
R McCarty et al.
Hypertension (Dallas, Tex. : 1979), 27(5), 1115-1120 (1996-05-01)
To examine the contribution of the sympathetic nervous system to the development of hypertension, we injected spontaneously hypertensive rat (SHR) pups and normotensive Wistar-Kyoto rat (WKY) pups twice daily with saline (1.0 mL/kg SC) or terazosin (0.5 mg/kg SC), an
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica